Improving the discovery of drugs that target protein interactions.
Streamlining PPI Inhibitor Discovery via Chemically Enhanced Phage Display
This study is looking for new types of medicines that can better fight diseases like cancer by targeting how proteins interact with each other, using a special method to find helpful peptides that could work better than traditional treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston College NIH-funded |
| Lab location | 1 site (Chestnut Hill, United States) |
| Project ID | NIH-11001110 on NIH RePORTER |
What this research studies
This research focuses on developing new therapeutic drugs that can effectively target protein-protein interactions (PPIs), which are crucial in various diseases, including cancer. The approach utilizes chemically enhanced phage display to rapidly screen peptide libraries for potential PPI inhibitors. By exploring peptides as an alternative to traditional antibody-based drugs, the research aims to overcome limitations such as stability and tissue penetration, ultimately leading to more effective treatments. Patients may benefit from new drugs that are easier to administer and more effective in targeting disease mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers or conditions where protein-protein interactions play a significant role in disease progression.
Not a fit: Patients with conditions unrelated to protein-protein interactions or those who do not respond to peptide-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of innovative drugs that more effectively treat cancers and other diseases by targeting protein interactions.
How similar studies have performed: Previous research has shown promise in using peptide-based drugs to target protein interactions, indicating that this approach could be a viable and innovative strategy.
Where this research is happening
Chestnut Hill, United States
- Boston College — Chestnut Hill, United States (Active)
Researchers
- Principal investigator: Gao, Jianmin — Boston College
- Study coordinator: Gao, Jianmin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.